drugset / Trial / NCT05280444

Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma

NCT05280444

Phase 2/3 Unknown 216 enrolled Zhongda Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this real-world study is to evaluate the safety and efficacy of lipiodol-TACE with idarubicin for hepatocellular carcinoma.

Timeline

Start
2022-05-28
Primary completion
2023-06-30
Completion
2023-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Idarubicin Small molecule 10 mg Other
Subject Idarubicin Small molecule 20 mg Other